MedTrace Logo

Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

NCT06589752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-09-19

No results posted yet for this study

Summary

This replication of the NefIgArd trial of TRF-budesonide aims to use real-world data to evaluate the efficiency and safety of TRF-budesonide in the treatment of IgA nephropathy, from completing real-world research to providing real-world evidence.

Conditions

Interventions

DRUG

TARPEYO 4 MG Delayed Release Oral Capsule

TARPEYO dispensing claim for any dose is exposure

DRUG

RAS inhibitor

RASi dispensing claim for any dose is reference

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2024-09-05
Completion
2024-09-05
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06589752 on ClinicalTrials.gov